Occam Places Gary Glick as Chairman at CHARM Therapeutics
On the heels of a robust Series A raise co-led by F-Prime Capital and OrbiMed, CHARM Therapeutics has added veteran biotech entrepreneur Gary Glick as Chairman. CHARM intends to utilize 3D deep learning in small molecule drug discovery with an initial emphasis on cancer.
Gary Glick, President and CEO of Odyssey Therapeutics, is a formidable chemist and serial biotech entrepreneur. He has founded several successful companies, including Scorpion and IFM Therapeutics. While CEO of IFM, the company progressed three programs from ideation to clinical development and executed several major transactions, including the sale of oncology assets to Bristol-Myers Squibb in a transaction valued more than $2.3B. Prior to Odyssey, in 2020, he co-founded and launched Scorpion Therapeutics. During his tenure as CEO, Scorpion grew to nearly 50 employees and raised $270M across two financings.
Glick is the author of more than 100 papers, the inventor on 54 issued U.S. patents, and the recipient of numerous awards recognizing his scientific contributions and accomplishments as a life science executive. Gary received his Ph.D. in Organic Chemistry from Columbia University and completed an NIH postdoctoral fellowship in Organic Chemistry at Harvard University.
Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.